UCL Stem Cell Research
- Home
- Group Leaders
- Disease Areas
- Infrastructure
- Activities
- Seminars and Events
- Research Highlights
- Industrial Partners
- International Collaborations
- Science Policy Advice
- Public Engagement
- MSc and PhD programmes
- Undergraduate courses
- Educational Materials
- External Scientific Advisory Board
- Awards
- Contact
- Links
- Member Login
Industrial Partners
|
Moorfields Eye Hospital - Advanced Cell Technology
collaboration in new retinal stem cell trial for Stargardt's Macular Dystrophy On 23 January 2012, Advanced Cell Technology (ACT) announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells. The surgery was performed on Friday, Jan. 20, at the Moorfields Eye Hospital in London by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. More at UCL Institute of Ophthalmology and ACT On 22 September 2011, the UK Medicines and Healthcare Products Regulatory
Agency (MHRA) gave the go-ahead to new trials of an experimental retinal stem
cell treatment for young patients suffering from Stargardt's Macular Dystrophy,
to be performed at Moorfields Eye Hospital. Read the ACT press release |
|
|
UCL-Astra Zeneca to develop regenerative medicines for diabetic retinopathy
|
|
|
UCL–Pfizer to develop pioneering stem cell sight therapies On 24 April 2009, the London Project to Cure Blindness led by Professor Pete Coffey entered a collaboration with Pfizer to advance the development of stem cell-based therapies for age-related macular degeneration. Read more at UCL News |
|
Page last modified on 23 jan 12 14:41
